a b s t r a c t DYSIS II CHD was a longitudinal, observational study in 6794 patients from 18 countries. They were attending an outpatient physician appointment for coronary heart disease (CHD). 6370 patients (93.8%) were on active lipid lowering therapy (LLT). The
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Low-density lipoprotein cholesterol Treatment target Global Region Statins mean atorvastatin dose equivalent was 25 mg per day and 10.5% received ezetimibe in combination with a statin. The mean lowdensity lipoprotein cholesterol (LDL-C) level was 88 mg/dL, with 29.4% of patients displaying a level below the 70 mg/dL target for very high-risk subjects. Conclusion: While more than 90% of patients with CHD were on lipid lowering drugs, only three out of ten patients achieved their LDL-C target value.
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Value of the data
These data have been collected under real life conditions across the world. Stratification per country can help to facilitate a scientific dialogue for the benefit of coronary patients in these countries, but also help to compare treatment standards between geographies of the world.
The data presented can help to guide treatment decisions for novel lipid lowering agents.
Data
See Fig. 1 and Tables 1 and 2. 2. Experimental design, materials and methods DYSIS II CHD was a multicenter, longitudinal, observational study that included 6794 patients from 18 countries in Europe, the Middle East, South-, Southeast-and East-Asia [1] .
The study was approved by the relevant ethics committees and carried out in agreement with local laws.
Inclusion criteria were as follows: 1) provision of written informed consent, 2) aged Z18, 3) attending an outpatient appointment for stable CHD 2012-2014, 4) availability of a full fasting or non fasting lipid profile from within the previous 12 months, and 5) not participating in a clinical trial.
The ESC/EAS dyslipidemia guidelines (2011) were used as a reference in order to determine target value attainment [2] . Low density lipoprotein (LDL-C) treatment target thus was o70 mg/dl. Use of Legend: BMI, body mass index; CI, confidence interval; OR, odds ratio. LLT was documented, including use of statin and combination therapy. We also determined the statin dose administered, calculated as atorvastatin equivalent doses [3] . Data were collected in an electronic case report form and processed in a central web-based database at the Institut für Herzinfarktforschung, Ludwigshafen, Germany. It was used for both collection and storage of the data. SAS version 9.3 (Cary, NC, USA) was used for performing the calculations. Data are presented as absolute numbers and percentages (n/N). Between-group differences were evaluated using a chi squared test. Multivariable logistic regression was used to calculate odds ratios for factors predictive of LDL-C target attainment. Both the results of the full model and a stepwise forward selection model are given.
